Recent Updates
Recently added Catalysts

GFH375

Phase 2

Pancreatic Cancer | Small molecule | Oncology |cbdMD, Inc.|Last Updated: Aug 25, 2026

Target and mechanism

ModalitySmall molecule

Also known as ArmA:GFH375, Arm B:GFH375, Arm C:GFH375

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment120

FDA Designations

No designations recorded

Clinical trial landscape

GFH375 · 1 trial · 1 indication

Phase 2 1
NCT07784374A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D MutationPancreatic Cancer
NOT YET_RECRUITING120 Analytics
PHASE2NOT YET_RECRUITING
A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
Pancreatic Cancer
NCT07784374120
Unlock trial analytics

Study Endpoints

Primary Endpoints

PFS
Up to approximately 2 years

Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) according to RECIST v1.1

Weight
Baseline, From first study treatment to Week 12

Percentage Change in Body Weight From Baseline at Week 12

Secondary Endpoints

OS
Up to approximately 3 years
PFS
Up to approximately 2 years
ORR
Up to approximately 2 years
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
GFH375+GFH276EXPERIMENTAL -
GFH375+GFS202AEXPERIMENTAL -
GFH375EXPERIMENTAL -

Interventions

NameTypeDescription
GFH375DRUGadministered per protocol-specified schedule
GFH276DRUGadministered per protocol-specified schedule
GFS202ADRUGadministered per protocol-specified schedule
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 80 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Able to provide written informed consent prior to any study-related procedures. * Male or female subjects aged between 18 and 80 years (inclusive) at the time of informed consent. * Histologically or cytologically confirmed pancreatic adenocarcinoma. * Estimated life expectanc...

Countries:China
Unlock Eligibility Criteria

Competitive Landscape -Pancreatic Cancer 178 trials

Top 20 of 67 competitors

CompanyTickerTrialsLead PhaseDrugs
Revolution Medicines, Inc.RVMD9PHASE3RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan
Arcus Biosciences, Inc.RCUS3PHASE3Quemliclustat, Nab-paclitaxel, Gemcitabine
Pfizer Inc.PFE7PHASE2tisotumab vedotin, pembrolizumab, carboplatin, cisplatin
AstraZeneca PLCAZN9PHASE2AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan
AbbVie, Inc.ABBV4PHASE2TTX-030, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine
AngioDynamics, Inc.ANGO2PHASE3Modified FOLFIRINOX Regimen
Bristol-Myers Squibb CompanyBMY4PHASE2Navlimetostat, Gemcitabine, Nab-paclitaxel
Immuneering Corp. Class AIMRX2PHASE3Atebimetinib, GnP, mGnP
RenovoRx, Inc.RNXT1PHASE3Gemcitabine, nab-paclitaxel
BioNTech SE Sponsored ADRBNTX2PHASE2Pumitamig, Nab-paclitaxel, Gemcitabine, mFOLFIRINOX
Veracyte, Inc.VCYT1PHASE3Tislelizumab
ArriVent BioPharma, Inc.AVBP3PHASE2JAB-21822
Merck & Co., Inc.MRK2PHASE2Belzutifan
Eli Lilly and CompanyLLY7PHASE1LY4101174
Exelixis, Inc.EXEL1PHASE2Zanzalintinib, Everolimus
Agenus Inc.AGEN4PHASE2AGEN1423, Botensilimab, Gemcitabine, Nab-paclitaxel
HUTCHMED (China) Limited Sponsored ADRHCM1PHASE2Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib with Nab-paclitaxel, and Gemcitabine
Incyte CorporationINCY3PHASE2Ruxolitinib, Capecitabine, Regorafenib
Jazz Pharmaceuticals Public Limited CompanyJAZZ1PHASE2Zanidatamab
ImmunityBio IncIBRX1PHASE2N-803, Aldoxorubicin, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine
Unlock Competitive Intelligence